Related references
Note: Only part of the references are listed.Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
Felicia Cosman et al.
MAYO CLINIC PROCEEDINGS (2017)
Observations following discontinuation of long-term denosumab therapy
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
Erik Fink Eriksen et al.
BONE (2016)
Improvement of cancellous bone microstructure in patients on. teriparatide following alendronate pretreatment
Astrid Fahrleitner-Pammer et al.
BONE (2016)
Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
J. N. Tsai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
P. D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancel the denosumab holiday
M. R. McClung
OSTEOPOROSIS INTERNATIONAL (2016)
Teriparatide and denosumab combination therapy and skeletal metabolism
L. Idolazzi et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Coupling signals between the osteoclast and osteoblast how are messages transmitted between these temporary visitors to the bone surface?
Natalie A. Sims et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study
Joy N. Tsai et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
Yanfei L. Ma et al.
BONE (2014)
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
C. Roux et al.
BONE (2014)
Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density-The CONFORS Study
Christian Muschitz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches
Felicia Cosman
CURRENT OSTEOPOROSIS REPORTS (2014)
Antiresorptives Overlapping Ongoing Teriparatide Treatment Result in Additional Increases in Bone Mineral Density
Christian Muschitz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial
Yong-Ki Min et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2013)
Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy A Randomized Open-Label Trial
Chris Recknor et al.
OBSTETRICS AND GYNECOLOGY (2013)
Combination therapy with risedronate and teriparatide in male osteoporosis
Marcella D. Walker et al.
ENDOCRINE (2013)
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
Matthew Austin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Six Months of Parathyroid Hormone (1-84) Administered Concurrently Versus Sequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial
Anne L. Schafer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy A Randomized Controlled Trial
Andrea Z. LaCroix et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
David L. Kendler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Joel S. Finkelstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
J. J. Stepan et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin
Gerardo Heiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy
LG Ste-Marie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial
C Deal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
MR McClung et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography
B Borah et al.
BONE (2004)
Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial
JA Cauley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women - A randomized controlled trial
SL Greenspan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy -: A randomized controlled trial
BH Ascott-Evans et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
F Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Share Paper
